OncoSil Medical Limited (ASX:OSL)

Market Cap	18.43M
Revenue (ttm)	1.91M
Net Income (ttm)	-12.60M
Shares Out	4.61B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	303,374
Average Volume	2,546,625
Open	0.0040
Previous Close	0.0040
Day's Range	0.0040 - 0.0040
52-Week Range	0.0040 - 0.0150
Beta	1.09
RSI	42.68
Earnings Date	May 30, 2025

About OncoSil Medical

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OSL

Financial Performance

In 2024, OncoSil Medical's revenue was 1.57 million, an increase of 6.68% compared to the previous year's 1.47 million. Losses were -11.91 million, 5.03% more than in 2023.